Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk, Hims and Hers Shares Tumble on Severed Ties
10:55am, Monday, 23'rd Jun 2025
Novo Nordisk A/S (NYSE:NVO) stock is down 5.3% to trade at $69.90 at last check, after the drugmaker's obesity drug CagriSema showed no clear advantage over Eli Lilly's (LLY) Zepbound.
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern
09:10am, Monday, 23'rd Jun 2025
On Sunday, The New England Journal of Medicine (NEJM) published results from Novo Nordisk A/S‘ NVO phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with o
Hims & Hers stock crashes over 20% on Wegovy shocker
08:56am, Monday, 23'rd Jun 2025
Hims & Hers Health (NYSE: HIMS) stock has plunged sharply after Novo Nordisk (NYSE: NVO) announced it was severing ties with the telehealth firm over concerns about the distribution of its weight loss
Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
08:36am, Monday, 23'rd Jun 2025
Novo Nordisk accuses the telehealth company of breaking a law related to drug compounding.
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
08:20am, Monday, 23'rd Jun 2025
Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. Novo Nordis
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy ® that put patient safety at risk Novo Nordisk won't stop
Novo Nordisk ends collaboration with Hims & Hers over weight loss drug sale
07:46am, Monday, 23'rd Jun 2025
Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.
Novo Nordisk's New Obesity Drug Beats Wegovy Weight Loss in Early Trial
06:25am, Monday, 23'rd Jun 2025
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Novo Nordisk shares fall as obesity pipeline faces investor scrutiny
06:21am, Monday, 23'rd Jun 2025
Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly's
Novo Nordisk's new obesity drug hits high efficacy marks, but investors stay cautious
03:32am, Monday, 23'rd Jun 2025
Novo Nordisk (NYSE:NVO) delivered promising data over the weekend for its next-generation weight-loss injection, CagriSema, showing it can achieve weight reductions on par with the most effective trea
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
09:02am, Sunday, 22'nd Jun 2025
Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, includ
Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational C
China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds
03:52pm, Saturday, 21'st Jun 2025
Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a simila
Novo Nordisk: Ignored GLP-1 Leader Is Now A Deep Value Play
09:30am, Saturday, 21'st Jun 2025
NVO's bottom has finally materialized after the painful halving from June 2024 peaks, as the GLP-1 compounding/supply headwinds moderate. This is significantly aided by the expanded partnership with n
Novo Nordisk And Its Real Value
03:29am, Saturday, 21'st Jun 2025
Novo Nordisk remains fundamentally strong with robust earnings growth, high ROE, ROIC, and gross margins, despite recent CEO change and short-term market concerns. The stock appears undervalued, tradi
